+97%

est. 2Y upside i

HealthcareSeries D+

Empowering women. Period.

Rank

#433

Sector

FemTech, Digital Health, Diagnostics

Est. Liquidity

~3Y

Data Quality

Data: Medium

Moderate potential but high risk.

Last updated: July 19, 2026

Bull (25%)+180%

FDA clearance and category leadership drive multiple expansion to 8x; revenue reaches $7.5M. Exit value $60M vs entry $15M, net of 20% dilution yields 180% upside.

Base (55%)+130%

Multiple converges to 5x, revenue $7.5M, exit $37.5M. Net of 20% dilution yields 130% upside.

Bear (20%)-100%

Multiple compresses to 3x, exit $22.5M below $24.3M preference stack; common stock recovers -100%.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

162%

Total funding $24.3M outweighs valuation $15M by 162%, meaning common stock is worthless in any exit below $24.3M.

Dilution Risk

high

Likely need for additional raise within 24 months (runway ~1 year from Apr 2024), estimated 20% dilution.

Secondary Liquidity

none

No secondary market observed; employee shares likely illiquid until exit.

Questions to Ask at the Interview

Strategic questions based on Qvin's data — designed to show you've done your homework.

  • 1

    “How do you plan to drive adoption beyond early adopters and into mainstream OB/GYN practices?”

  • 2

    “What are the unit economics of the Q-Pad (COGS, test revenue) and how do you scale margins?”

  • 3

    “Given the capital intensity and preference overhang, what is the realistic path to liquidity for employees and at what valuation?”

Community

Valuation Sentiment

Our model estimates +97% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.